Clinical trials: Neuroprotection
Cardiac Arrest
Inhaled Nitric Oxide for Cardiac Arrest in Pediatrics and Adults (iNOCAPA)
This study is a multi-center, double blind, randomized controlled trial of inhaled nitric oxide (iNO) in children and adults with cardiac arrest (CA).
- Trial name
- iNOCAPA (NCT05868109)
- Testing
- inhaled nitric oxide (iNO)
- Where
- 4 sites in Canada
- Volunteers
- 40 people
- Sponsor
- The Hospital for Sick Children
Ataxia Telangiectasia, Growth Failure
Status of Growth Hormone/ Insulin-like Growth Factor-1 (GH/IGF-1) Axis and Growth Failure in Ataxia Telangiectasia (AT)
This study will evaluate the status of the growth hormone/ insulin-like growth factor-1 (GH/IGF-1) axis in relation to growth failure, body weight and composition and neuroprotection in children with Ataxia telangiectasia (AT).
- Trial name
- GHAT (NCT01052623)
- Testing
- Somatropin, Clonidine, L-Arginin-Hydrochloride, Estradiol valerate
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Johann Wolfgang Goethe University Hospital
Spinal Cord Injuries
Cerebrospinal Fluid (CSF) Drainage and Cytokine Profiling in the Treatment of Acute Spinal Cord Injury (SCI)
The overall purpose of this pilot study is to evaluate CSF drainage as a potential neuroprotective strategy after acute spinal cord injury (SCI).
- Trial name
- NCT00135278
- Testing
- CSF Drainage, No CSF Drainage
- Where
- Canada
- Volunteers
- 31 people
- Sponsor
- University of British Columbia
Language Delay, Language; Developmental Disorder, Expressive
Intranasal Inhalations of M2 Macrophage Soluble Factors in Children With Developmental Speech Disorders
The investigators have designed an innovative proof-of-concept trial designed to provide data as to whether the speech difficulties in children with developmental dysphasia (DD) are improved with intranasal inhalations of…
- Conditions
- Language Delay, Language; Developmental Disorder, Expressive, Language; Developmental Disorder, Receptive, Autism Spectrum Disorder
- Trial name
- NCT04689282
- Testing
- Bioactive Factors, Produced by M2 Type Macrophages (M2-BFs).
- Where
- Russia
- Volunteers
- 14 people
- Sponsor
- Russian Academy of Medical Sciences
Dexmedetomidine
Dexmedetomidine and Neuroprotection in Children Undergoing General Anesthesia
Neuroapoptosis is induced by the administration of anesthetic agents to the young brain. Recent studies showed that the a2-adrenoceptor agonist, dexmedetomidine plays a trophic role during development and is neuroprotective in…
- Trial name
- NCT03234660
- Testing
- Dexmedetomidine Hydrochloride, control
- Where
- South Korea
- Volunteers
- 60 people
- Sponsor
- Seoul National University Hospital
Extreme Prematurity
Preterm Erythropoietin Neuroprotection Trial (PENUT Trial)
Recombinant human erythropoietin (Epo) is a promising novel neuroprotective agent. Epo decreases neuronal programmed cell death resulting from brain injury; it has anti-inflammatory effects, increases neurogenesis, and protects…
- Trial name
- PENUT (NCT01378273)
- Testing
- Epo, Control
- Where
- 19 sites in United States
- Volunteers
- 941 people
- Sponsor
- University of Washington
Hypoxic Ischemic Encephalopathy
Efficacy of Erythropoietin to Improve Survival and Neurological Outcome in Hypoxic Ischemic Encephalopathy
The purpose of this study is to determine the efficacy of high dose Erythropoietin to improve survival and neurologic outcome in asphyxiated term newborn undergoing cooling.
- Trial name
- Neurepo (NCT01732146)
- Testing
- erythropoietin Beta
- Where
- France
- Volunteers
- 120 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Brain Injuries, Head Injury
Magnesium Sulfate For Brain Injury
The purpose of the study is to determine whether magnesium sulfate, given within 8 hours of a moderate or severe traumatic brain injury improves survival, decreases the number of people developing seizures, improves the…
- Conditions
- Brain Injuries, Head Injury, Brain Concussion
- Trial name
- NCT00004730
- Testing
- magnesium sulfate
- Where
- United States
- Sponsor
- University of Washington
Parkinson's Disease
NET-PD LS-1 Creatine in Parkinson's Disease
The purpose of this trial is to determine if the nutritional supplement creatine slows the progression of Parkinson's disease over time.
- Trial name
- NCT00449865
- Testing
- creatine
- Where
- 50 sites in United States, Canada
- Volunteers
- 1,741 people
- Sponsor
- University of Rochester
Hypoxic-Ischaemic Encephalopathy, Perinatal Asphyxia
Hypoxic-Ischemic Encephalopathy Therapy Optimization in Neonates for Better Neuroprotection With Inhalative CO2
This is a Phase I, open-label, single center trial to evaluate the feasibility and safety of low concentration CO2 gas mixture (5% CO2 + 95% air) inhalation in asphyxiated, cooled, mechanically ventilated newborns at risk of…
- Conditions
- Hypoxic-Ischaemic Encephalopathy, Perinatal Asphyxia, Hypocapnia
- Trial name
- HENRIC (NCT02700854)
- Testing
- 5% carbon-dioxide inhalation
- Where
- Hungary
- Volunteers
- 10 people
- Sponsor
- Semmelweis University
Hypoxic Ischaemic Encephalopathy
Neuroprotective Effects of Hypothermia Combined With Inhaled Xenon Following Perinatal Asphyxia
This is a randomised controlled trial in newborn infants with perinatal asphyxial encephalopathy assessing whether a combination of hypothermia and inhaled xenon preserve cerebral metabolism and structure.
- Trial name
- TOBYXe (NCT00934700)
- Testing
- Xenon gas
- Where
- United Kingdom
- Volunteers
- 92 people
- Sponsor
- Imperial College London
White Matter Injury, Brain Injury, Fetus and Neonate
Neonatal White Matter Injury Trial (WRAP)
The researchers are investigating a new treatment for white matter injury, which is a common type of brain injury in premature babies. The drug, clemastine, is experimental.
- Conditions
- White Matter Injury, Brain Injury, Fetus and Neonate, Neonatal Brain Injury, Periventricular Leukomalacia
- Trial name
- WRAP (NCT07688746)
- Testing
- Clemastine fumarate
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Bridget LaMonica Ostrem, M.D., Ph.D.
Neonatal Encephalopathy
Sildenafil Administration to Treat Neonatal Encephalopathy
Despite improvements in neonatal care, birth asphyxia in term newborns remains a serious condition causing significant mortality and long-term morbidity, including cerebral palsy and mental retardation.
- Trial name
- SANE-01 (NCT02812433)
- Testing
- Sildenafil, Ora-Blend
- Where
- Canada
- Volunteers
- 28 people
- Sponsor
- McGill University Health Centre/Research Institute of the McGill University Health Centre
Neonatal Respiratory Failure
Hypothermia During ECMO to Decrease Brain Injury
Newborn infants with severe respiratory failure are treated with extracorporeal membrane oxygenation (ECMO), a modified form of cardiopulmonary bypass.
- Trial name
- NCT01675388
- Testing
- Hypothermia
- Where
- United States
- Sponsor
- Sood, Beena G., MD, MS
Brain Injury, Myocardial Injury
Preconditioning With Hyperbaric Oxygen in Cardiovascular Surgery
Animal studies have shown that preconditioning with hyperbaric oxygen can induce central nervous system and heart ischemic tolerance.
- Trial name
- NCT00817791
- Testing
- Hyperbaric oxygen pretreatment (GR2200)
- Volunteers
- 49 people
- Sponsor
- Xijing Hospital
Congenital Heart Disease, Hypoplastic Left Heart Syndrome
Erythropoetin Neuroprotection for Neonatal Cardiac Surgery
Brain problems occur in neonatal open heart surgery with a frequency of 20-70%, seen on neurological examination, brain imaging such as magnetic resonance imaging (MRI), or long term development problems such as learning…
- Conditions
- Congenital Heart Disease, Hypoplastic Left Heart Syndrome, Transposition of the Great Arteries, Aortic Arch Hypoplasia or Interruption
- Trial name
- NCT00513240
- Testing
- Erythropoetin, Normal saline
- Where
- United States
- Volunteers
- 62 people
- Sponsor
- Baylor College of Medicine
Cardiac Arrest, Brain Injury
Duration of Hypothermia for Neuroprotection After Pediatric Cardiac Arrest
In this study, children who survive cardiac arrest will be evaluated whether 24 or 72 hours of whole body hypothermia (cooling) during recovery is better to help prevent brain injury and improve outcome.
- Trial name
- NCT00797680
- Testing
- 72 hours hypothermia, 24 hours hypothermia
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Pittsburgh
Congenital Heart Disease in Children, Neuroprotection
Cerebrum and Cardiac Protection With Allopurinol in Neonates With Critical Congenital Heart Disease Requiring Cardiac Surgery With Cardiopulmonary Bypass
Neurodevelopmental impairment due to delayed brain development and brain injury is a fundamental problem in children with critical congenital heart disease (CCHD).
- Trial name
- CRUCIAL (NCT04217421)
- Testing
- Allopurinol, Mannitol
- Where
- 4 sites in Netherlands
- Volunteers
- 236 people
- Sponsor
- dr. M.J.N.L. Benders
Superficial Siderosis
Therapeutic Antioxidant Supplementation
A remotely administered study, non-randomized, non-blinded, controlled parallel assignment phase 2 trial to determine if oral inosine or inositol hexaphosphate will provide an effective long-term therapy to combat or slow neural…
- Trial name
- TAS-SS21 (NCT04890808)
- Testing
- Inosine, IP6
- Volunteers
- 50 people
- Sponsor
- Superficial Siderosis Research Alliance Inc.
Premature Birth, Extreme Prematurity
The Pilot Experimental Study of the Neuroprotective Effects of Exosomes in Extremely Low Birth Weight Infants
To study the safety and efficacy of intranasal administration of exosomes derived from mesenchymal stromal cells on long-term neurodevelopmental outcome in extremely low birth weight infants born at gestational age 25/0-27/6…
- Conditions
- Premature Birth, Extreme Prematurity, Preterm Intraventricular Hemorrhage, Hypoxia-Ischemia, Cerebral
- Trial name
- NCT05490173
- Testing
- Exosomes derived from mesenchymal stromal cells (MSCs)
- Where
- Russia
- Volunteers
- 10 people
- Sponsor
- Federal State Budget Institution Research Center for Obstetrics, Gynecology and Perinatology Ministry of Healthcare